Promotional series organised and fully funded by Novartis Pharmaceuticals UK Ltd.

Following recent updates in guidance and the treatment pathway for secondary prevention of cardiovascular disease¹, this series focuses on the use of inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia .

Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin,
• or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet ²

Viewing the resources in the series will provide you with an opportunity to further understand the NICE technology appraisal for inclisiran³ and our panel of experts will propose practical ways of implementing this guidance.

The series consists of four assets:

MLR ID: 221550 | September 2022

The effect of inclisiran on cardiovascular morbidity and mortality has not yet been determined.

References

1. Khatib R and Neely D. AAC Clinical Subgroup: Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD 2021. Summary-of-national-guidance-for-lipid-management-for-primary-and-secondary-prevention-of-cardiovascular-disea.pdf (england.nhs.uk) [Accessed September 2022]

2. Leqvio® Summary of Product Characteristics 2022.

3. NICE Guidance TA733, 2021. Available at https://www.nice.org.uk/guidance/ta733. [Accessed August 2022]